This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Calliditas Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Calliditas Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-SEK 8.89
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Feb 24

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Jan 12

Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Dec 22

Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Sep 22

What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Aug 19

Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

May 26

Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Feb 24

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Nov 25

Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Aug 24

Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

Aug 03

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CALTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CALTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Calliditas Therapeutics Piyasaya Karşı Temettü Getirisi

CALTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CALTX)	n/a
Pazarın Alt %25'i (SE)	1.5%
Pazarın En İyi %25'i (SE)	4.6%
Sektör Ortalaması (Pharmaceuticals)	2.3%
Analist tahmini (CALTX) (3 yıla kadar)	0%

Önemli Temettü: CALTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CALTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CALTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CALTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

This company listing is no longer active

Calliditas Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Calliditas Therapeutics AB (publ) Announces Board Changes

Nasdaq Stockholm Decides to Delist Calliditas Therapeutics

Calliditas Therapeutics AB (publ)(OM:CALTX) dropped from OMX Nordic All-Share Index

Calliditas Resolves to Apply for Delisting of the Common Shares from Nasdaq Stockholm, ADS from Nasdaq Global Select Market

Asahi Kasei Intends to Promote Delisting of the Shares in Calliditas Therapeutics from Nasdaq Stockholm

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Calliditas Therapeutics AB Announces the European Commission Grant Full Marketing Authorization for Kinpeygo

Calliditas Therapeutics AB Announces Positive Transform Phase 2b Topline Data in Primary Biliary Cholangitis

Forecast to breakeven in 2025

Chief Medical Officer recently sold kr10m worth of stock

Calliditas Therapeutics AB (publ) Provides Setanaxib Patent Update

Calliditas Partner Stada Receives Positive Chmp Opinion Recommending Full Approval for Kinpeygo[®] for the Treatment of Iga Nephropathy

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and other shareholders for SEK 11.2 billion.

Asahi Kasei Corporation (TSE:3407) made an offer to acquire Calliditas Therapeutics AB (publ) (OM:CALTX) from BVF Partners, Linc AB (publ), Stiftelsen Industrifonden and others shareholders for SEK 11.2 billion.

New major risk - Share price stability

Calliditas Therapeutics AB (Publ) Reaffirms Earnings Guidance for the Year Ending December 31, 2024

Forecast breakeven date pushed back to 2025

Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results

Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®

Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO

Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calliditas Therapeutics AB Provides Patent Update

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Calliditas Therapeutics AB Provides Preliminary Revenue Guidance for the Full Year 2023

Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost

Calliditas Therapeutics AB Announces Full FDA Approval of TARPEYO

Calliditas Therapeutics AB (publ) Receives Notice of Allowance for United States Patent Application Covering TARPEYO

Calliditas Therapeutics AB Announces the Initiation of A Phase 2 Clinical Study to Evaluate Setanaxib in Alport Syndrome

Price target decreased by 7.3% to kr220

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Calliditas Therapeutics AB Presents Additional Data Analyses from NefIgArd Phase 3 Trial at American Society of Nephrology Kidney Week 2023

Calliditas Therapeutics' Nomination Committee Composition for the Agm 2024

New minor risk - Share price stability

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

Calliditas Therapeutics AB Presents Data from the Nefigard Phase 3 Trial At the 17Th International Symposium on Iga Nephropathy (Iigann) Tokyo 2023

STADA and Calliditas Therapeutics AB Announce Submission of Request to EMA for CHMP to Convert Conditional Marketing Authorization for Kinpeygo to Standard, or Full, Marketing Authorization

Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?

Calliditas Therapeutics AB (publ) to Report Q1, 2024 Results on May 16, 2024

Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon®? for the Treatment of IgA Nephropathy

Calliditas Therapeutics AB (publ) announces that FDA Grants Priority Review for Full Approval of Tarpeyo for the Treatment of IgA Nephropathy

What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Calliditas Therapeutics AB (Publ) Provides Sales Guidance for Year Ending December 31, 2023

Calliditas Therapeutics AB (publ) Announces Supportive Interim Data from Phase 2 Head and Neck Cancer Trial with Lead Nox Inhibitor Candidate, Setanaxib

Independent Chairman recently bought kr1.1m worth of stock

Calliditas Therapeutics AB Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO

Calliditas Therapeutics AB (publ) Announces Board Changes

Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%

Forecast breakeven date pushed back to 2024

Calliditas Therapeutics AB (Publ) Provides Earnings Outlook for the Year Ending December 31, 2023

No longer forecast to breakeven

Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?

Calliditas Therapeutics AB (publ) Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy

Price target increased to kr247

Calliditas Therapeutics AB (publ) to Report Nine Months, 2023 Results on Nov 16, 2023

Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Insider recently sold kr532k worth of stock

Forecast to breakeven in 2023

Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?

Calliditas' Partner Everest Medicine's New Drug Application for Nefecon Is Accepted by the China Nmpa

Calliditas Therapeutics AB (Publ) Announces Nomination Committee Composition for the Agm 2023

Calliditas Therapeutics AB (publ) Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO[®] (budesonide) in IgA Nephropathy

Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%

Calliditas Therapeutics AB (publ) to Report Q1, 2023 Results on May 17, 2023

Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?

Calliditas Therapeutics AB (publ) Announces European Commission Approves Kinpeygo® for Adults with Primary IgA Nephropathy

Calliditas Therapeutics AB Announces Executive Appointments

Consensus forecasts updated

Price target increased to kr242